Friday, 17 Aug 2018

You are here

MTX Doubles Hepatotoxicity Risk in Psoriasis Patients

A study from the University of Pennsylvania Perelman School of Medicine was published in the Journal of Investigative Dermatology showing that the risk of incident liver disease doubled when patients with psoriasis (PsO) or psoriatic arthritis (PsA) take methotrexate (MTX), but not when MTX is used in rheumatoid arthritis. (Citation source https://buff.ly/2i9qizC)

This was a comparative cohort study of patients with psoriasis (N=197,130), PsA (N=12,308), RA (N=54,251), and matched controls (N=1,279,754). Researchers calculated the adjusted hazard ratios for any liver disease in these patients with or without systemic therapy (ST).  Liver disease was defined as any liver disease, non-alcoholic fatty liver disease (NAFLD), and cirrhosis (any etiology).

 Overall, 6% of psoriasis patients were prescribed systemic therapy, as were 53% of people with psoriatic arthritis and 61% of people with rheumatoid arthritis. MTX was the most commonly prescribed ST. 

The Liver Disease Hazard ratios were: 

Diseasewith MTX RxHazard Ratio
PsONo1.37
PsOYes1.97
PsANo1.38
PsAYes1.49
RANo 1.49
RA Yes0.96

 

Incident NAFLD was highest in patients with PsO prescribed a ST (2.23) and PsA with ST (2.11). Risk of cirrhosis was highest among patients with PsO with an ST (2.62) and PsA without a ST (3.15).

Increasing body surface area in PsO further increased the prevalence of liver disease and cirrhosis (p for trend <0.001).

More so than RA, PsO and PsA are associated with liver disease, particularly NAFLD and cirrhosis, and this was true even among patients without systemic therapy exposure.

Compared to people without chronic inflammatory diseases, people with psoriasis were 37% more likely to develop liver disorders. When psoriasis patients took methotrexate, they had roughly twice  (67%) the odds of liver damage.  For rheumatoid arthritis, there was no increased risk of liver disease when people took methotrexate, but when they didn’t they had 49% higher odds of liver damage.

There was no data on deaths from liver disease in this study

 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Rheumatologists' Comments

Increase HR in patients with no ST (eg in RA or in cirrhosis in PsA) could be confounded as clinicians may actively avoid MTX in patients with existing liver disease or cirrhosis.

More Like This

Back Pain in Psoriatic Arthritis

A single center study of psoriatic arthritis patients has shown that rheumatologist-judged inflammatory back pain (IBP) and criteria defining IBP may not perform well when ascertaining axial involvement in PsA patients. 

Minimal Disease Activity: The Goal in PsA

The majority of patients with psoriatic arthritis (PsA) who achieved a state of minimal disease activity (MDA) after 6 months of treatment with adalimumab (Humira) maintained that response through 24 months, a large observational study found.

Liver Disease Increased in Psoriasis

An observational case-control study has shown that psoriasis is associated with an increased prevalence of nonalcoholic fatty liver disease (NAFLD).

A single center, outpatient dermatology clinic studied 151 patients with psoriasis and 51 control subjects with ultrasonography to diagnose NAFLD.

Best of 2017: Cause of Death in Ankylosing Spondylitis

A French population based study of ankylosing spondylitis (AS) was report in the Journal of Rheumatology.

They analyzed the death certificates and cause of death in 2940 AS patients over 3 different decades (1969-78; 1979-99; 2000-2009).

The mortality rate of AS remained stable over time.

Ixekizumab Effective in Ankylosing Spondylitis

Eli Lilly announced today the results of the COAST-W trial showing that ixekizumab (Taltz) was effective in a Phase 3 study Ankylosing Spondylitis (AS) patients who had an inadequate response or intolerance to tumor necrosis factor (TNFi) inhibitor therapy.